Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not recruitingRare disease

Study Comparing INBRX-101 and Human Alpha1-Proteinase Inhibitor for Adults with Alpha-1 Antitrypsin Deficiency Emphysema

Verified siteRegistered drug
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying a condition known as Alpha-1 Antitrypsin Deficiency (AATD) Emphysema. This is a genetic disorder that can lead to lung problems, including emphysema, which is a type of chronic lung disease. The study is testing a new treatment called INBRX-101, which is a concentrate for solution for infusion. This treatment is being compared to an existing therapy known as plasma-derived Alpha1-Proteinase Inhibitor (A1PI) augmentation therapy. The goal of the study is to evaluate how well INBRX-101 works in maintaining certain protein levels in the blood, which are important for lung health, over a period of up to 32 weeks.

Participants in the study will receive either the new treatment, INBRX-101, or the existing A1PI therapy. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving which treatment. This helps ensure that the results are unbiased. The study will also include a placebo group, which will receive a solution that does not contain the active treatment. Throughout the study, participants will have regular check-ups to monitor their health and the effects of the treatment.

The study aims to gather information on the safety and effectiveness of INBRX-101 compared to the current standard treatment. It will also look at how the body processes the new treatment and whether it causes any immune reactions. By the end of the study, researchers hope to better understand if INBRX-101 can be a beneficial treatment option for people with AATD emphysema.

The research process

The trial runs in 7 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Joining the study

    Upon joining the study, the patient will be informed about the trial's purpose and procedures. The patient will be required to provide informed consent, acknowledging understanding of the study and agreeing to participate.

  2. Step 2

    Initial assessment

    The patient will undergo an initial assessment to confirm eligibility. This includes verifying age, diagnosis of Alpha-1 Antitrypsin Deficiency (AATD), evidence of emphysema, and lung function tests to ensure FEV1 is between 30% and 80% of the predicted value. The patient must also be a non-smoker.

  3. Step 3

    Randomization

    The patient will be randomly assigned to receive either INBRX-101 or a plasma-derived Alpha1-Proteinase Inhibitor (A1PI) therapy. This process ensures that each participant has an equal chance of receiving either treatment.

  4. Step 4

    Treatment administration

    The patient will receive the assigned treatment through an infusion. INBRX-101 is administered as a concentrate for solution for infusion at a concentration of 50mg/ml. The alternative treatment, Respreeza, is a powder and solvent for solution for infusion. The frequency and dosage will be determined by the study protocol and medical staff.

  5. Step 5

    Treatment period

    The treatment period will last up to 32 weeks. During this time, the patient will receive regular infusions and attend scheduled visits for monitoring and assessment of treatment effects.

  6. Step 6

    Monitoring and assessments

    Throughout the study, the patient will undergo regular monitoring to assess the pharmacodynamic effects on serum functional AAT levels, safety, and any adverse events. Blood samples may be taken to measure the concentration of AAT and to check for any immune responses to the treatment.

  7. Step 7

    Completion of study

    Upon completion of the treatment period, the patient will have a final assessment to evaluate the overall effects of the treatment. This includes measuring changes in AAT levels and reviewing any side effects experienced during the study.

Who can join the trial?

5 criteria

  • Must be a male or female between 18 and 80 years old.
  • Must have a diagnosis of **Alpha-1 Antitrypsin Deficiency (AATD)**, which is a genetic condition affecting the lungs.
  • Must show signs of **emphysema** caused by AATD. Emphysema is a lung condition that makes it hard to breathe.
  • Must have a **FEV1** (Forced Expiratory Volume in 1 second) between 30% and 80% of what is predicted for a healthy person. FEV1 is a measure of how much air you can forcefully exhale in one second.
  • Must be a current non-smoker, meaning you do not smoke cigarettes at the time of the study.

Who cannot join the trial?

8 criteria

  • Patients who have a known allergy or severe reaction to the study medication or its ingredients cannot participate.
  • Individuals with a history of certain lung diseases, other than **Alpha-1 Antitrypsin Deficiency (AATD) Emphysema**, are not eligible.
  • Participants who have had a recent lung infection or illness that affects breathing may be excluded.
  • People who are currently taking medications that could interfere with the study treatment are not allowed to join.
  • Patients with a history of drug or alcohol abuse may be excluded from the study.
  • Individuals with certain medical conditions that could affect the study results or their safety might not be eligible.
  • Pregnant or breastfeeding women cannot participate in the study.
  • Participants who are unable to follow the study procedures or attend scheduled visits may be excluded.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

  • INBRX-101

    is an investigational medication being studied for its effects on patients with a condition called Alpha-1 Antitrypsin Deficiency (AATD) emphysema. This medication is designed to help increase the levels of a protein called functional AAT in the blood, which may help protect the lungs from damage.

  • Alpha1-Proteinase Inhibitor (A1PI) Augmentation Therapy

    is a treatment used for patients with AATD emphysema. It involves giving patients additional A1PI, a protein that helps protect the lungs from damage. This therapy aims to maintain adequate levels of A1PI in the blood to help prevent further lung damage.

What is already known about the treatment

INBRX-101 – This medication is administered intravenously and is currently being studied in clinical trials for its effectiveness in treating Alpha-1 Antitrypsin Deficiency (AATD) Emphysema. It is in the experimental phase, with ongoing research to understand its pharmacokinetics, pharmacodynamics, and safety profile. The main therapeutic indication is to manage AATD emphysema by maintaining functional levels of alpha-1 antitrypsin in the blood. At the molecular level, INBRX-101 works by supplementing the deficient protein, thereby reducing lung damage. It is classified as a protein replacement therapy.

Investigated diseases

Alpha-1 Antitrypsin Deficiency (AATD) Emphysema – This is a genetic disorder that affects the lungs and liver, primarily leading to emphysema, a type of chronic obstructive pulmonary disease (COPD). It occurs due to a deficiency of the protein alpha-1 antitrypsin, which protects the lungs from damage caused by enzyme activity. Without enough of this protein, the lungs are more susceptible to damage from environmental factors like smoke and pollution. Over time, this can lead to the destruction of lung tissue, causing breathing difficulties and reduced lung function. The progression of the disease can vary, with some individuals experiencing rapid decline while others have a slower progression. Symptoms often include shortness of breath, wheezing, and chronic cough.
Trial detailsLast updated 7 Oct 2026
Age18+ yearsPhasePhase IITrial ID2023-508084-76-00Protocol codeINBRX101-01-201Estimated enrolment94 patientsSponsorSanofi AATD Inc.

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.